Byline: Market Analysis & Forecast Becton Dickinson doesn’t get the hype of AI stocks or biotech moonshots. But quietly, it remains one of the most important healthcare infrastructure companies in the world. Recent CEO commentary has focused heavily on: operational efficiency margin expansion innovation in diagnostics and medical devices long-term healthcare demand growth And beneath the surface, BDX may be evolving into: 👉 a high-quality healthcare compounder with improving profitability The News: Efficiency and Innovation Driving the Story Management has recently emphasized: improving supply chain execution cost optimization accelerating high-margin product categories stronger cash flow generation The company continues investing aggressively in: diagnostics biosciences medication delivery systems smart medical technologies This matters because BDX isn’t just selling products. 👉 It’s embedded deeply into the global healthcare system. Th...